{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T22:39:40Z","timestamp":1785451180263,"version":"3.56.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Von Willebrand Factor (VWF) multimers are cleaved into smaller and less coagulant forms by the metalloprotease ADAMTS13. The aim of this study was to investigate the association between VWF and ADAMTS13 and mortality in dialysis patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We prospectively followed 956 dialysis patients. VWF levels and ADAMTS13 activity were measured. Cox proportional hazard analyses were used to calculate hazard ratios (HRs) with 95\u2009% confidence intervals (CIs) to investigate the association between quartiles of VWF levels and ADAMTS13 activity and all-cause mortality. HRs were adjusted for age, sex, body mass index, cardiovascular disease, dialysis modality, primary kidney disease, use of antithrombotic medication, systolic blood pressure, albumin, C-reactive protein and residual GFR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the 956 dialysis patients, 288 dialysis patients died within three years (mortality rate 151 per 1000 person-years). The highest quartile of VWF as compared with lower levels of VWF was associated with a 1.4-fold (95\u00a0%CI 1.1\u20131.8) increased mortality risk after adjustment. The lowest quartile of ADAMTS13 activity as compared with other quartiles was associated with a 1.3-fold (95\u00a0%CI 1.0-1.7) increased mortality risk after adjustment. The combination of the highest VWF quartile and lowest ADAMTS13 quartile was associated with a 2.0-fold (95\u00a0%CI 1.3-3.0) increased mortality risk as compared with the combination of the lowest VWF quartile and highest ADAMTS13 quartile.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>High VWF levels and low ADAMTS13 activity were associated with increased mortality risks in dialysis patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12882-021-02420-z","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T09:03:03Z","timestamp":1623834183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Von Willebrand factor, ADAMTS13 and mortality in dialysis patients"],"prefix":"10.1186","volume":"22","author":[{"given":"Gurbey","family":"Ocak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Roest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne C.","family":"Verhaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten B.","family":"Rookmaaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Blankestijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem Jan W.","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Fijnheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie C.","family":"P\u00e9qu\u00e9riaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedo W.","family":"Dekker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,16]]},"reference":[{"issue":"6","key":"2420_CR1","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1055\/s-0038-1648506","volume":"67","author":"ZM Ruggeri","year":"1992","unstructured":"Ruggeri ZM, Ware J. The structure and function of von Willebrand factor. Thromb Haemost. 1992;67(6):594\u20139.","journal-title":"Thromb Haemost"},{"key":"2420_CR2","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev.biochem.67.1.395","volume":"67","author":"JE Sadler","year":"1998","unstructured":"Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395\u2013424.","journal-title":"Annu Rev Biochem"},{"issue":"6","key":"2420_CR3","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1182\/blood.V98.6.1654","volume":"98","author":"HE Gerritsen","year":"2001","unstructured":"Gerritsen HE, Robles R, Lammle B, et al. Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood. 2001;98(6):1654\u201361.","journal-title":"Blood"},{"issue":"6","key":"2420_CR4","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1182\/blood.V98.6.1662","volume":"98","author":"K Fujikawa","year":"2001","unstructured":"Fujikawa K, Suzuki H, McMullen B, et al. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood. 2001;98(6):1662\u20136.","journal-title":"Blood"},{"issue":"4","key":"2420_CR5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.hoc.2007.06.003","volume":"21","author":"HM Tsai","year":"2007","unstructured":"Tsai HM. Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency. Hematol Oncol Clin North Am. 2007;21(4):609\u201332. v.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"4","key":"2420_CR6","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/j.1538-7836.2008.02902.x","volume":"6","author":"JT Crawley","year":"2008","unstructured":"Crawley JT, Lane DA, Woodward M, et al. Evidence that high von Willebrand factor and low ADAMTS-13 levels independently increase the risk of a non-fatal heart attack. J Thromb Haemost. 2008;6(4):583\u20138.","journal-title":"J Thromb Haemost"},{"issue":"12","key":"2420_CR7","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1161\/ATVBAHA.109.192740","volume":"29","author":"AM Kucharska-Newton","year":"2009","unstructured":"Kucharska-Newton AM, Couper DJ, Pankow JS, et al. Hemostasis, inflammation, and fatal and nonfatal coronary heart disease: long-term follow-up of the atherosclerosis risk in communities (ARIC) cohort. Arterioscler Thromb Vasc Biol. 2009;29(12):2182\u201390.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"2420_CR8","doi-asserted-by":"publisher","first-page":"e55175","DOI":"10.1371\/journal.pone.0055175","volume":"8","author":"P Willeit","year":"2013","unstructured":"Willeit P, Thompson A, Aspelund T, et al. Hemostatic factors and risk of coronary heart disease in general populations: new prospective study and updated meta-analyses. PLoS One. 2013;8(2):e55175.","journal-title":"PLoS One"},{"issue":"22","key":"2420_CR9","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1053\/euhj.2001.3237","volume":"23","author":"PH Whincup","year":"2002","unstructured":"Whincup PH, Danesh J, Walker M, et al. von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J. 2002;23(22):1764\u201370.","journal-title":"Eur Heart J"},{"issue":"25","key":"2420_CR10","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1182\/blood-2015-05-643338","volume":"126","author":"MA Sonneveld","year":"2015","unstructured":"Sonneveld MA, de Maat MP, Portegies ML, et al. Low ADAMTS13 activity is associated with an increased risk of ischemic stroke. Blood. 2015;126(25):2739\u201346.","journal-title":"Blood"},{"issue":"6","key":"2420_CR11","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1111\/j.1538-7836.2010.03863.x","volume":"8","author":"MC van Schie","year":"2010","unstructured":"van Schie MC, MP DEM, Dippel DW, et al. von Willebrand factor propeptide and the occurrence of a first ischemic stroke. J Thromb Haemost. 2010;8(6):1424\u20136.","journal-title":"J Thromb Haemost"},{"issue":"16","key":"2420_CR12","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1161\/CIRCULATIONAHA.106.635029","volume":"115","author":"I Tzoulaki","year":"2007","unstructured":"Tzoulaki I, Murray GD, Lee AJ, et al. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. Circulation. 2007;115(16):2119\u201327.","journal-title":"Circulation"},{"issue":"6","key":"2420_CR13","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1182\/blood-2011-09-380618","volume":"119","author":"HM Andersson","year":"2012","unstructured":"Andersson HM, Siegerink B, Luken BM, et al. High VWF, low ADAMTS13, and oral contraceptives increase the risk of ischemic stroke and myocardial infarction in young women. Blood. 2012;119(6):1555\u201360.","journal-title":"Blood"},{"issue":"4","key":"2420_CR14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.blre.2014.04.003","volume":"28","author":"MA Sonneveld","year":"2014","unstructured":"Sonneveld MA, de Maat MP, Leebeek FW. Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. Blood Rev. 2014;28(4):167\u201378.","journal-title":"Blood Rev"},{"issue":"6","key":"2420_CR15","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1093\/ndt\/gfr735","volume":"27","author":"NC Pequeriaux","year":"2012","unstructured":"Pequeriaux NC, Fijnheer R, Gemen EF, et al. Plasma concentration of von Willebrand factor predicts mortality in patients on chronic renal replacement therapy. Nephrol Dial Transplant. 2012;27(6):2452\u20137.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"2420_CR16","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1097\/MBC.0b013e32836261dd","volume":"24","author":"RM Holden","year":"2013","unstructured":"Holden RM, Tuttle A, Burbidge T, et al. Quantitative and qualitative changes of von Willebrand factor and their impact on mortality in patients with end-stage kidney disease. Blood Coagul Fibrinolysis. 2013;24(7):719\u201326.","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"12","key":"2420_CR17","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1161\/ATVBAHA.116.308225","volume":"36","author":"MA Sonneveld","year":"2016","unstructured":"Sonneveld MA, Franco OH, Ikram MA, et al. Von Willebrand Factor, ADAMTS13, and the Risk of Mortality: The Rotterdam Study. Arterioscler Thromb Vasc Biol. 2016;36(12):2446\u201351.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"10","key":"2420_CR18","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1111\/jth.14254","volume":"16","author":"G Ocak","year":"2018","unstructured":"Ocak G, Noordzij M, Rookmaaker MB, et al. Mortality due to bleeding, myocardial infarction and stroke in dialysis patients. J Thromb Haemost. 2018;16(10):1953\u201363.","journal-title":"J Thromb Haemost"},{"key":"2420_CR19","first-page":"37","volume":"184","author":"H Van Der Meersch","year":"2016","unstructured":"Van Der Meersch H, De Bacquer D, Vriese AS. Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis. AmHeart J. 2016;184:37\u201346.","journal-title":"AmHeart J"},{"issue":"10","key":"2420_CR20","first-page":"3816","volume":"27","author":"D Zimmerman","year":"2012","unstructured":"Zimmerman D, Sood MM, Rigatto C, et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. NephrolDialTransplant. 2012;27(10):3816\u201322.","journal-title":"NephrolDialTransplant"},{"key":"2420_CR21","doi-asserted-by":"crossref","unstructured":"van Dijk PC, Jager KJ de. C, F., et al. Renal replacement therapy in Europe: the results of a collaborative effort by the ERA-EDTA registry and six national or regional registries. NephrolDialTransplant. 2001;16(6):1120\u20139.","DOI":"10.1093\/ndt\/16.6.1120"},{"issue":"10","key":"2420_CR22","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jclinepi.2006.01.009","volume":"59","author":"KG Moons","year":"2006","unstructured":"Moons KG, Donders RA, Stijnen T, et al. Using the outcome for imputation of missing predictor values was preferred. J Clin Epidemiol. 2006;59(10):1092\u2013101.","journal-title":"J Clin Epidemiol"},{"key":"2420_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1471-2288-9-57","volume":"9","author":"A Marshall","year":"2009","unstructured":"Marshall A, Altman DG, Holder RL, et al. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol. 2009;9:57.","journal-title":"BMC Med Res Methodol"},{"issue":"3","key":"2420_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/0962280206075304","volume":"16","author":"MG Kenward","year":"2007","unstructured":"Kenward MG, Carpenter J. Multiple imputation: current perspectives. Stat Methods Med Res. 2007;16(3):199\u2013218.","journal-title":"Stat Methods Med Res"},{"issue":"10","key":"2420_CR25","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1093\/ndt\/gft221","volume":"28","author":"MC de Goeij","year":"2013","unstructured":"de Goeij MC, van Diepen M, Jager KJ, et al. Multiple imputation: dealing with missing data. Nephrol Dial Transplant. 2013;28(10):2415\u201320.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"2420_CR26","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11239-012-0682-1","volume":"34","author":"DR Rios","year":"2012","unstructured":"Rios DR, Carvalho MG, Figueiredo RC, et al. ADAMTS13 and Von Willebrand factor in patients undergoing hemodialysis. J Thromb Thrombolysis. 2012;34(1):73\u20138.","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"2420_CR27","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/s11239-012-0719-5","volume":"33","author":"DR Rios","year":"2012","unstructured":"Rios DR, Fernandes AP, Figueiredo RC, et al. Relationship between ABO blood groups and von Willebrand factor, ADAMTS13 and factor VIII in patients undergoing hemodialysis. J Thromb Thrombolysis. 2012;33(4):416\u201321.","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"2420_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s11239-007-0073-1","volume":"26","author":"M Polatli","year":"2008","unstructured":"Polatli M, Cakir A, Cildag O, et al. Microalbuminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. J Thromb Thrombolysis. 2008;26(2):97\u2013102.","journal-title":"J Thromb Thrombolysis"},{"issue":"6","key":"2420_CR29","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1160\/TH09-06-0376","volume":"103","author":"TN Bongers","year":"2010","unstructured":"Bongers TN, Emonts M, de Maat MP, et al. Reduced ADAMTS13 in children with severe meningococcal sepsis is associated with severity and outcome. Thromb Haemost. 2010;103(6):1181\u20137.","journal-title":"Thromb Haemost"},{"issue":"11","key":"2420_CR30","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1111\/j.1538-7836.2007.02743.x","volume":"5","author":"JA Kremer Hovinga","year":"2007","unstructured":"Kremer Hovinga JA, Zeerleder S, Kessler P, et al. ADAMTS-13, von Willebrand factor and related parameters in severe sepsis and septic shock. J Thromb Haemost. 2007;5(11):2284\u201390.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2420_CR31","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000322120","volume":"125","author":"ES Hatzipantelis","year":"2011","unstructured":"Hatzipantelis ES, Athanassiou-Metaxa M, Gombakis N, et al. Thrombomodulin and von Willebrand factor: relation to endothelial dysfunction and disease outcome in children with acute lymphoblastic leukemia. Acta Haematol. 2011;125(3):130\u20135.","journal-title":"Acta Haematol"},{"issue":"8\u20139","key":"2420_CR32","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S0753-3322(00)00006-8","volume":"54","author":"M Morganti","year":"2000","unstructured":"Morganti M, Carpi A, Amo-Takyi B, et al. Von Willebrand\u2019s factor mediates the adherence of human tumoral cells to human endothelial cells and ticlopidine interferes with this effect. Biomed Pharmacother. 2000;54(8\u20139):431\u20136.","journal-title":"Biomed Pharmacother"},{"issue":"25","key":"2420_CR33","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1016\/j.jacc.2010.12.033","volume":"57","author":"V Roldan","year":"2011","unstructured":"Roldan V, Marin F, Muina B, et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol. 2011;57(25):2496\u2013504.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2420_CR34","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ijcard.2012.09.056","volume":"168","author":"MK Freynhofer","year":"2013","unstructured":"Freynhofer MK, Gruber SC, Bruno V, et al. Prognostic value of plasma von Willebrand factor and its cleaving protease ADAMTS13 in patients with atrial fibrillation. Int J Cardiol. 2013;168(1):317\u201325.","journal-title":"Int J Cardiol"},{"key":"2420_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jclinepi.2020.03.015","volume":"123","author":"Y de Jong","year":"2020","unstructured":"de Jong Y, Ramspek CL, van der Endt VHW, et al. A systematic review and external validation of stroke prediction models demonstrates poor performance in dialysis patients. J Clin Epidemiol. 2020;123:69\u201379.","journal-title":"J Clin Epidemiol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02420-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-021-02420-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-021-02420-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T09:05:50Z","timestamp":1623834350000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-021-02420-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,16]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2420"],"URL":"https:\/\/doi.org\/10.1186\/s12882-021-02420-z","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,16]]},"assertion":[{"value":"11 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has conformed to the ethical principles of the Declaration of Helsinki and was approved by the Medical Ethics Committee of the Leiden University Medical Center. And all patients had signed informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"222"}}